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Background:  While there is an evidence that the anti-inflammatory properties of spironolactone can attenuate proteinuria in 
type 2 diabetes, its effects on vascular endothelial growth factor (VEGF) expression in diabetic nephropathy have not been clear-
ly defined. In this study, we examined the effects of spironolactone, losartan, and a combination of these two drugs on albumin-
uria, renal VEGF expression, and inflammatory and oxidative stress markers in a type 2 diabetic rat model. 
Methods:  Thirty-three Otsuka-Long-Evans-Tokushima-Fatty (OLETF) rats were divided into four groups and treated with dif-
ferent medication regimens from weeks 25 to 50; OLETF diabetic controls (n=5), spironolactone-treated (n=10), losartan-treat-
ed (n=9), and combination of spironolactone- and losartan-treated (n=9). 
Results:  At week 50, the albumin-to-creatinine ratio was significantly decreased in the losartan and combination groups com-
pared to the control OLETF group. No decrease was detected in the spironolactone group. There was a significant reduction in 
renal VEGF, transforming growth factor (TGF)-β, and type IV collagen mRNA levels in the spironolactone- and combination 
regimen-treated groups. Twenty-four hour urine monocyte chemotactic protein-1 levels were comparable in all four groups but 
did show a decreasing trend in the losartan and combination regimen groups. Twenty-four hour urine malondialdehyde levels 
were significantly decreased in the spironolactone- and combination regimen-treated groups.
Conclusion:  These results suggest that losartan alone and a combined regimen of spironolactone and losartan could ameliorate 
albuninuria by reducing renal VEGF expression. Also, simultaneous treatment with spironolactone and losartan may have pro-
tective effects against diabetic nephropathy by decreasing TGF-β and type IV collagen expression and by reducing oxidative stress 
in a type 2 diabetic rat model. 
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INTRODUCTION
It is well known that the renin-angiotensin-aldosterone (RAA) 
system is an important pathway of progression in cardiovas-
cular disease, diabetic nephropathy, and chronic renal disease 
through a mechanism of inflammation, fibrosis, and necrosis 
[1,2]. For this reason, angiotensin converting enzyme inhibi-
tor (ACEI) and angiotensin receptor blocker (ARB) are effec-
tive in the treatment of chronic heart failure and diabetic ne-
phropathy [3-6]. However, long term use of RAA system block-
ade therapies have been shown to result in increased plasma 
aldosterone levels in 40% of patients with diabetic nephropa-
thy and 20% of patients with chronic renal failure. This condi-
tion is referred to as the aldosterone escape phenomenon [7]. 
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The proteinuria-reducing effects of ACEI and ARB are also 
decreased in these patients [8]. It is expected that a reduction 
in aldosterone levels alone could be a crucial treatment target 
in diabetic nephropathy. 
  Recent data suggests that an aldosterone receptor blocker 
could reduce proteinuria by decreasing various growth factors 
[9,10]. It has also been reported that aldosterone receptor block-
er treatment can reduce proteinuria in patients with chronic 
renal disease who did not respond to ACEI therapy [11].
  Vascular endothelial growth factor (VEGF), a strong angio-
genic factor, is known to play a major role in the neovascular-
ization of atherosclerotic plaques and solid cancers [12,13], and 
in the progression of diabetic nephropathy [14]. Although it is 
reported that ARB treatment protects against diabetic nephrop-
athy by reducing VEGF [15,16], there is no data demonstrat-
ing the effect of aldosterone receptor blocker therapy on renal 
VEGF expression.
  In this study, we investigated the effects of losartan, spirono-
lactone, and a combination of these two drugs on albuminuria 
and renal VEGF expression in a type 2 diabetic rat model.
METHODS
Experimental rats
Thirty-three male Otsuka-Long-Evans-Tokushima-Fatty rats 
(OLETF rats; Otsuka Pharmaceutical, Tokushima, Japan) were 
divided into four groups and received different medication 
regimens: spironolactone (50 mg/kg/day), losartan (20 mg/kg/
day), or a combination of the two from weeks 25 to 50. The 
first group consisted of untreated diabetic OLETF controls 
(CO; n=5), the second group was spironolactone-treated dia-
betic rats (SPR; n=10), the third group was losartan-treated 
diabetic rats (LO; n=9) and the fourth group was spironolac-
tone and losartan combination-treated diabetic rats (COM; 
n=10). All groups had access to standard rat chow and drink-
ing water, ad libitum. This research protocol was approved by 
the animal ethics committee of the Yonsei University Wonju 
College of Medicine (Wonju, Korea).
Basic parameters
Body weights and blood glucose levels (Surestep; Lifescan Inc., 
Milpitas, CA, USA) were recorded at weeks 15, 30, and 50. 
Blood pressure was measured using tail-cuff plethysmography 
at weeks 30 and 50. Twenty-four hour urines were collected at 
weeks 15, 30, and 50 for measuring and urine protein levels 
(Roche Molecular Biochemicals, Indianapolis, IN, USA) and 
albumin-creatinine ratio (ACR) values (by ELISA; Shibayagi, 
Shibukawa, Japan) were determined.
Kidney extraction
At week 50, all experimental rats were sacrificed under anes-
thesia by intraperitoneal injection of Zoletil
® (30 mg/kg). One 
kidney was rapidly fixed in 4% paraformaldehyde for 24 hours 
and paraffin-embedded for immunohistochemical study and 
histologic examination. The other kidney was flash frozen in 
liquid nitrogen for subsequent protein and RNA extraction. 
Frozen kidneys were stored at -70°C until analyzed by Western 
blot and real time reverse transcription-polymerase chain reac-
tion (RT-PCR) for VEGF, transforming growth factor (TGF)-β, 
and collagen type IV.
Histologic examination of kidney
Paraffin-embedded kidney tissues were cut into 7 μm sections 
and stained with periodic acid-Schiff (PAS). A glomerular ma-
trix index (GMI) score was measured and the degree of sclero-
sis for each glomerulus was graded from 0 to 4 as follows [17]: 
grade 0: normal; grade 1: mild sclerosis (less than 25% of glom-
erulus); grade 2: moderate sclerosis (25 to 50% of glomerulus); 
grade 3: moderate-severe sclerosis (50 to 75% of glomerulus); 
grade 4: severe sclerosis (75 to 100% of glomerulus). Ten glom-
eruli were scored in each kidney section.
Immunohistochemical staining of VEGF
Tissue sections were affixed onto slides and deparaffinized for 
immunohistochemical staining. The slides were then trans-
ferred to a 10-mmol/L citrate buffer solution (pH 6.0), washed 
with distilled water and blocked with 0.05% H2O2-methanol 
for 15 minutes. A 1:1,000 dilution of anti-VEGF monoclonal 
antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA) was applied and slides were incubated at room tempera-
ture. A biotinylated secondary antibody from a rat ABC stain-
ing kit (Santa Cruz Biotechnology Inc.) was used followed by 
incubation in a horseradish peroxidase Avidin-Biotin Com-
plex solution (ABC reagent). The slides were then incubated 
in a peroxidase substrate containing 0.05% 3,3ʹ-diaminoben-
zidine tetrahydrochloride (DAB). Stained sections were viewed 
with a light microscope equipped with a charge-coupled de-
vice camera (Pulnix America Inc., Sunnyvale, CA, USA) and 
glomerular VEGF optical densities were measured by image 
analysis.132
Lee MY, et al.
Diabetes Metab J 2011;35:130-137 http://e-dmj.org
Real time RT-PCR 
Total RNA was extracted from frozen kidney tissues using 
TRIzol
® LS (GIBCO-BRL, Grand Island, NY, USA) and then 
reverse transcribed into cDNA using oligo-(dT) primers (Pro-
mega, Madison, WI, USA). Real time RT-PCR was performed 
using a SYBR Green RT-PCR kit (Qiagen, Valencia, CA, USA) 
and analyzed with a Rotor-Gene RG-3000 cycler (Corbett Re-
search, Mortlake, NSW, Australia). Primer oligonucleotide se-
quences for VEGF, TGF-β, collagen type IV and GAPDH are 
as follows:
      VEGF forward: 5ʹ-GTATATCTTCAAGCCGTCCTGT-
GTG-3ʹ, VEGF reverse: 5ʹ-GATCCGCATGATCTGCA 
TAGTGAC-3ʹ, TGF-β forward: 5ʹ-TGAGTGGCTGT
CTTTTGACG-3ʹ, TGF- β reverse: 5ʹ-TGGGACTGAT
CCCATTGATT-3ʹ, Collagen type IV forward: 5ʹ-CCA 
GGATTCCAAGGTCAGAA-3ʹ, Collagen type IV reverse: 
5ʹ-CCCTGGTTCTCCTTTGATGA-3ʹ, GAPDH forward: 
5ʹ-TCAGGTCATCACTATCGGCAATG-3ʹ, GAPDH re-
verse: 5ʹ-GGAATTGAATGTAGTTTCATGGATGC-3ʹ
  Real-time RT-PCR amplification was performed with one 
cycle at 95°C for 10 minutes followed by 40 cycles that consist-
ed of denaturation for 15 seconds at 94°C, annealing for 30 
seconds at 58°C and extension for 30 seconds at 72°C. After 
rinse and melting processes, fluorescent products were detect-
ed during the 92°C extension cycle. The cycle threshold (∆Ct=
Ct VEGF-Ct β-actin) of each sample was calculated and the relative 
change ratio determined using an mRNA ratio of VEGF/
β-actin.
Western blot analysis
The cortex of each kidney was homogenized in RIPA buffer, 
incubated on ice for 20 minutes and centrifuged at 15,000 rpm 
to remove cellular debris. 10 µg samples of protein lysate were 
electrophoresed on 10% SDS-PAGE gels at 100 V and trans-
ferred onto polyvinylidene fluoride (PVDF) membranes for 1 
hour at 280 mA in a Tris-based buffer. Non-specific binding 
sites were blocked with a 5% non-fat dried milk solution for 1 
hour. Membranes were incubated overnight with anti-rat 
β-actin antibody (1:2,000 dilution; Cell Signaling Technology 
Inc., Beverly, MA, USA) or VEGF antibody (1:1,000 dilution; 
R&D System, Minneapolis, MN, USA) followed by incubation 
with anti-rabbit IgG or anti-goat IgG HRP antibodies. Signal 
was visualized using the ELC Western Blotting Analysis Sys-
tem (Amersham Biosciences, Buckinghamshire, UK).
Monocyte chemotactic protein-1 (MCP-1) and 
malondialdehyde (MDA)
Twenty-four hour urine MCP-1 levels were measured by quan-
titative sandwich ELISA (Biosource Inc., Camarillo, CA, USA) 
and used as an inflammatory marker. Urine MDA levels were 
measured by a rapid and sensitive fluorometric HPLC method 
and used as an oxidative stress marker [18]. 
Statistical analyses
All data are presented as mean±standard deviation. The data 
were analyzed statistically using one-way ANOVA and the 
Tukey test (multiple comparisons). All analyses were performed 
using a Windows-based, SPSS statistical package version 12.0 
(SPSS Inc., Chicago, IL, USA). P<0.05 was considered to be 
statistically significant.
RESULTS
Basic parameters of experimental rats
There were no significant differences in body weights and plas-
ma glucose levels at each time point. However, blood pressure 
levels of the COM group at week 50 were significantly lower 
than that of the CO group (Table 1). At weeks 15 and 30, there 
were no differences in 24-hour urine protein levels and ACR 
among all groups. At week 50, the LO and COM groups showed 
significant decreases in 24-hour urine protein levels and ACR, 
but the SPR group did not show reduced proteinuria and ACR 
when compared to the CO group (Table 1).
PAS staining of glomeruli and GMI score
Glomerular mesangial expansion was observed in the CO 
group compared to the other groups in PAS staining of glom-
eruli (Fig. 1A). The GMI scores were significantly decreased in 
all medicated groups compared to the CO group. Also, the 
COM group showed a marked decrease in GMI scores com-
pared to the SPR and LO groups (Fig. 1B).
Analysis of renal VEGF expression
Glomerular VEGF immunohistology revealed darker staining 
in the CO group compared to all of the medication treated 
groups (data not shown). The optical density of immunohisto-
chemical staining for VEGF in the LO and COM groups was 
significantly decreased compared to the CO group. The SPR 
group showed no appreciable difference when compared with 
the CO group (Fig. 2A). Real time RT-PCR analysis revealed 133
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Table 1. Clinical characteristics of experimental rats
15 wk  P value
a 30 wk P value
a 50 wk P value
a
Body weights, g
CO 554.60±105.06 608.00±45.49 602.00±46.04
SPR 489.30±40.27 0.425 589.90±74.11 0.631 596.00±80.71 0.889
LO 450.11±32.67 0.056 554.56±65.45 0.169 580.56±97.45 0.625
COM 465.11±68.46 0.077 570.78±86.22 0.335 577.22±78.54 0.573
Blood glucose, mg/dL
CO 113.82±17.02 140.20±17.41 140.80±20.29
SPR 118.60±17.01 0.574 137.60±18.07 0.777 146.60±35.30 0.651
LO 107.56±12.69 0.473 144.00±21.14 0.685 123.67±16.90 0.194
COM 119.89±18.08 0.484 136.67±12.67 0.706 127.69±16.88 0.193
Blood pressure, mm Hg
CO 117.60±4.75 132.11±10.26
SPR 116.40±9.01 0.760 132.11±13.23 0.538
LO 123.19±6.19 0.169 131.02±8.19 0.857
COM 117.38±6.71 0.957 109.30±10.24
b 0.001
ACR, mgAlb/mgCr
CO 0.50±0.13 1.01±0.96 4.35±1.19
SPR 0.39±0.31 0.262 0.93±0.62 0.736 3.26±1.74 0.282
LO 0.26±0.14 0.070 0.82±0.81 0.654 1.21±0.81
b 0.004
COM 0.43±0.11 0.491 0.96±0.95 0.956 1.06±0.98
b 0.002
24 hr urine protein levels, mg/day
CO 4.67±1.26 34.47±12.22 77.04±23.57
SPR 11.29±7.68 0.502 30.64±28.42 0.755 70.24±38.84 0.625
LO 10.49±4.71 0.688 27.91±23.99 0.601 29.23±22.14
b 0.002
COM 9.61±4.03 0.830 26.15±21.90 0.507 21.77±11.34
b <0.001
Data are presented by mean±standard deviation. 
CO, control Otsuka-Long-Evans-Tokushima-Fatty (OLETF) group; SPR, spironolactone-treated OLETF group; LO, losartan-treated OLETF 
group; COM, spironolactone- and losartan-treated OLETF group; ACR, albumin-creatinine ratio.
aP value vs. CO group, 
bP<0.05 compared with CO group. 
that VEGF mRNA expression was 0.35-fold in the SPR group, 
0.67-fold in the LO group, and 0.22-fold in the COM group 
when compared to the CO group (Fig. 2B). Western blot anal-
ysis, however, did not show any significant differences be-
tween the groups (Fig. 2C). 
Expression of TGF-β, type IV collagen
Real time RT-PCR analysis showed a significant decrease in 
TGF-β and type IV collagen mRNA expression in the SPR and 
COM groups compared to the CO group (Fig. 3). The SPR and 
COM groups also showed lower TGF-β mRNA expression 
than the LO group (Fig. 3). 
MCP-1 and MDA
At weeks 15 and 50, 24-hour urine MCP-1 levels were similar 
in all four groups but exhibited a decreasing trend in the LO 
and COM groups (Fig. 4A). At week 50, MDA levels were sig-
nificantly decreased in the COM group compared to the CO 
group (Fig. 4B).
DISCUSSION
Our data shows that losartan (ARB) alone or a combination 
treatment consisting of losartan and spironolactone (aldoste-
rone receptor blocker) can reduce proteinuria by reducing re-134
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Fig. 2. Analysis of renal vascular endothelial growth factor 
(VEGF) expression. (A) Optical densities of immunohistochemi-
cal staining for VEGF. (B) VEGF mRNA expression by real-time 
RT-PCR, and (C) Western blot for renal VEGF expression. Opti-
cal densities of glomerular VEGF in the LO and COM groups 
were significantly lower than those of the CO and SPR groups. 
Quantitative analysis revealed that expression of VEGF mRNA 
was 0.35-fold in the SPR group, 0.67-fold in the LO group, and 
0.22-fold in the COM group when compared with the CO group. 
Western blot did not show any differences among groups. CO, 
control Otsuka-Long-Evans-Tokushima-Fatty (OLETF) group; 
SPR, spironolactone-treated OLETF group; LO, losartan-treated 
OLETF group; COM, spironolactone- and losartan-treated 
OLETF group. 
aP<0.05 compared with CO group.
Fig. 1. PAS staining of glomeruli (A) and glomerular matrix indices (GMI) (B). PAS staining of glomeruli showed marked me-
sangial expansion and sclerosis in the CO group compared to other groups. Compared with the CO group, GMI scores were sig-
nificantly decreased in the SPR, LO, and COM groups. CO, control Otsuka-Long-Evans-Tokushima-Fatty (OLETF) group; SPR, 
spironolactone-treated OLETF group; LO, losartan-treated OLETF group; COM, spironolactone- and losartan-treated OLETF 
group. 
aP<0.05 compared with CO group, 
bP<0.05 compared with SPR group, 
cP<0.05 compared with LO group. Scale bar, 100 
μm, ×400.
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nal VEGF expression in a type 2 diabetic rat model.
  Diabetic nephropathy is the most common cause of end-
stage renal disease (ESRD). Since diabetic ESRD patients are 
more prone to cardiovascular mortality than other ESRD pa-
tients, early identification of diabetic nephropathy and prompt 
renoprotective treatment are critical for the prevention of end 
organ damage from diabetic nephropathy [19].
  It is well known that therapies with ACEI and ARB can re-
tard the progression of diabetic nephropathy, chronic heart 
failure and chronic renal failure by reducing blood pressure 
and by decreasing inflammatory and sclerosing effects [3-6]. 
Recent data indicates that spironolactone, an aldosterone re-
ceptor blocker, can reduce proteinuria by providing anti-in-
flammatory protection and by decreasing oxidative stress [10, 
20]. In our study, losartan- and the combination regimen-treat-
ed rat groups showed significant decreases in 24-hour urine 
protein levels and ACR while the spironolactone monotherapy 
group did not show these significant reductions. This discrep-
ancy may be explained by the differences in treatment initia-
tion time periods. Recent studies reported that treatment with 
aldosterone receptor blockers in the early stages of nephropa-
thy may reduce proteinuria but has no beneficial effects at later 
stages of the disease [21,22]. Since we administered spirono-
lactone treatment as late as week 25, its protective actions 
against diabetic nephropathy could have been inadequate 
compared to other studies that initiated treatment at earlier 
stages [10]. Another possible explanation is the different ef-
fects of spironolactone on hemodynamics and the fibrosis 
process. We observed decreased mesangial expansion and 
sclerosis in both the SPR and COM groups, which is consis-
tent with results from previous studies [23,24]. However, there 
were no differences in blood pressure between the groups. It 
could be explained that spironolactone can act on diabetic ne-
phropathy by non-hemodynamic mechanisms [25]. 
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  In diabetic nephropathy, VEGF expression may be increased 
by various growth factors including platelet derived growth 
factor and the accumulation of hyperglycemia-induced, ad-
vanced glycation end products [26,27]. Recent studies re-
vealed that ACEI and ARB can decrease proteinuria by reduc-
ing VEGF expression in type 2 diabetic rats [15,28]. Our data 
also suggests that a combination therapy with losartan and 
spironolactone may affect diabetic nephropathy by reducing 
VEGF expression despite incidental, disparate results between 
VEGF mRNA expression, immunohistochemical staining, 
and Western blot analysis. The discrepancies between mRNA 
expression and protein levels may be due to the interpretation 
of our data, which was in part based on inconsistent tissue 
sampling. While we could analyze individual glomeruli by im-
munohistochemical staining, we could not isolate glomeruli 
from tubules and interstitial tissue when extracting total RNA 
and protein for real time RT-PCR and Western blot analysis.
  Activation of the renin-angiotensin-aldosterone (RAA) sys-
tem causes increased production of reactive oxygen species 
through activation of the NADPH oxidase enzymatic complex 
in numerous tissues, including the kidney [29,30]. Angioten-
sin and other cytokines can also cause diabetic nephropathy 
through inflammatory mechanisms [29,30]. Blockade of the 
RAA system may have protective effects against diabetic ne-
phropathy through anti-oxidative and anti-inflammatory 
mechanisms [20]. In our study, only a combination therapy of 
losartan and spironolactone reduced MDA levels. MCP-1 lev-
els showed a slight decreasing trend in the combination regi-
men treated group but this was not statistically significant. 
These results indirectly explain that spironolactone and losar-
tan combination therapy may be an effective treatment regi-
men for diabetic nephropathy by reducing oxidative stress. 
  In conclusion, we suggest that ARB therapy in combination 
with ARB and aldosterone receptor blocker therapies may have 
protective effects against diabetic nephropathy by reducing 
VEGF expression. We also propose that combination treat-
ments could reduce proteinuria by anti-oxidative mechanisms 
and by decreasing TGF-β and type IV collagen expression.
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